Suppr超能文献

培哚普利联合硝苯地平与培哚普利联合氢氯噻嗪治疗轻至重度高血压:一项双盲多中心研究。培哚普利治疗联合多中心研究组。

Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.

作者信息

Letellier P, Overlack A, Agnes E, Desche P

机构信息

Département de Médecine Interne, Centre Hospitalier et Universitaire de Caen, France.

出版信息

J Hum Hypertens. 1994 Feb;8(2):145-9.

PMID:8207741
Abstract

Thiazide diuretics are considered as the choice drug to combine with ACE inhibitors for the treatment of hypertension. However, there is much evidence showing that the combination of ACE inhibitors with a calcium channel blocker is effective and safe. We compared the safety and efficacy of perindopril 8 mg once daily plus nifedipine SR 10 mg twice daily with perindopril 8 mg once daily plus hydrochlorothiazide (HCTZ) 12.5 mg once daily in a two phase three month study. After a one month placebo run-in period, patients whose DBP averaged 95-125 mmHg received perindopril 4 mg once daily for the first open phase (n = 524). After one month those whose DBP remained > 90 mmHg were prescribed perindopril 8 mg once daily for a second month. Among them, those whose DBP were still > 90 mmHg entered the second phase for one month, in a double-blind fashion. Fifty-three patients received HCTZ (BP: 161.2/99.2 +/- 2.0/0.9 mmHg), 57 received nifedipine (BP: 161.4/98.7 +/- 2.2/0.7 mmHg). Five patients withdrew due to side-effects, three patients in the perindopril plus nifedipine group and two in the perindopril plus HCTZ group. After one month there was a significant drop in BP (P < 0.01) in both groups: perindopril plus HCTZ (-13.9/-11.9 mmHg) and perindopril plus nifedipine (-12.1/-10.8 mmHg). Heart rate was not significantly modified: perindopril plus HCTZ (-1.30 beats/min), perindopril plus nifedipine (+0.54 beats/min). There were no significant difference between the two combinations for BP reduction and heart rate. The incidence of adverse experiences was similar in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

噻嗪类利尿剂被认为是与血管紧张素转换酶抑制剂(ACE抑制剂)联合用于治疗高血压的首选药物。然而,有许多证据表明,ACE抑制剂与钙通道阻滞剂联合使用是有效且安全的。在一项为期三个月的两阶段研究中,我们比较了每天一次服用8毫克培哚普利加每天两次服用10毫克硝苯地平缓释片与每天一次服用8毫克培哚普利加每天一次服用12.5毫克氢氯噻嗪(HCTZ)的安全性和有效性。在经过一个月的安慰剂导入期后,舒张压平均为95 - 125毫米汞柱的患者在第一个开放阶段每天一次服用4毫克培哚普利(n = 524)。一个月后,舒张压仍> 90毫米汞柱的患者在第二个月每天一次服用8毫克培哚普利。其中,舒张压仍> 90毫米汞柱的患者以双盲方式进入第二阶段,为期一个月。53名患者接受氢氯噻嗪治疗(血压:161.2 / 99.2 +/- 2.0 / 0.9毫米汞柱),57名患者接受硝苯地平治疗(血压:161.4 / 98.7 +/- 2.2 / 0.7毫米汞柱)。5名患者因副作用退出,培哚普利加硝苯地平组3名患者,培哚普利加氢氯噻嗪组2名患者。一个月后,两组血压均显著下降(P < 0.01):培哚普利加氢氯噻嗪组(-13.9 / -11.9毫米汞柱)和培哚普利加硝苯地平组(-12.1 / -10.8毫米汞柱)。心率无显著变化:培哚普利加氢氯噻嗪组(-1.30次/分钟),培哚普利加硝苯地平组(+0.54次/分钟)。两种联合用药在血压降低和心率方面无显著差异。两组不良事件的发生率相似。(摘要截取自250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验